Many thanks to our ATS 2024 Social Media Sponsor: Regeneron Healthcare Solutions. Learn more about the PATHWAYS Global Innovation Grant Initiative from Sanofi and Regeneron. https://lnkd.in/g4NmxcES #ad #ATS2024
American Thoracic Society’s Post
More Relevant Posts
-
You know the patient. But do you know the person? Bridge the gap between pharma perceptions and patient realities with experts Danielle Jacobs (formerly of AstraZeneca) and Bailey Kielarowski (Brandtrust) in our webinar on-demand: https://lnkd.in/gf5Kh6bV #Brandtrust #CustomerExperience #HumanCenteredDesign #BrandPurpose
To view or add a comment, sign in
-
-
The final part is here! We are sharing how to realize the value & benefits of #patientcentric trials: Integration and utilization can lead to financial impact by accelerating clinical trials getting drugs to the market faster. By embracing #patientcentric protocol design, we increase recruitment and retention by making trials more accessible and convenient for potential participants. Traditional methods of running a trials run often see 1 in 4 patients drop out because of trial length and complexity, burden and cost, and lack of support at trial site. However, with patient-centric approaches, we can bring trials to patients in their own community either conducting visits in their home or supporting a site in their community to participate in clinical research. By investing in patient-centric solutions, our pharma partners accelerate their timelines and speed up their clinical trials. Read more about it here https://lnkd.in/eVBizhxQ
To view or add a comment, sign in
-
-
In addition to using real-world evidence for clinical- and cost-effectiveness, it is also now being used for regulatory reviews of safety, efficacy, and quality. This article covers different types of decision-making using #RWD and #RWE across pharma companies, healthcare providers, healthcare systems, payers and health technology assessment agencies, regulators, and patients. https://lnkd.in/eyAkSNph By John Cai, MD, Ph.D., executive director of real-world data analytics and innovation, Merck
To view or add a comment, sign in
-
In 2023, deal volume declined across the #healthcare and life sciences sectors, but deal value rose because of notable megadeals in pharma and medtech. Learn more in our 2024 Global M&A Report.
Healthcare and Life Sciences M&A
bain.com
To view or add a comment, sign in
-
Founder HIPPO AI Foundation | Keynote Speaker, Lecturer | Social Entrepreneur | Desirable Future-ist | LinkedIn Top Healthcare Voice | Digital Health | Medical AI | Open Source
The potential sale or divestment of Flatiron Health by Roche underscores the challenges that arise when creating closed ecosystems within healthcare. While Flatiron's focus on oncology and real-world data has driven innovation, its ownership by a major pharmaceutical company like Roche has hindered broader collaboration across the industry. This situation highlights the inherent conflict between closed, proprietary ego-systems and the needs of healthcare, which thrives on open eco-systems that facilitate collaboration, data sharing, and cross-industry partnerships. Such open systems are crucial for fostering innovation and improving patient outcomes across the board. In contrast, closed ecosystems often restrict access, limit interoperability, and ultimately slow the progress that healthcare systems require to meet the demands of modern medicine. Moreover, the timing of this potential sale raises questions about whether Roche has already extracted the maximum value from Flatiron's data assets. If so, it suggests that Roche might see diminishing returns on the data and insights generated by Flatiron, further emphasizing the limitations of a closed system where the value of real-world data may plateau once its primary utility has been exhausted within a single corporate framework. This again underscores the importance of open ecosystems that allow continuous and broader utilization of data across multiple stakeholders in healthcare. Link in comments #digitalhealth
To view or add a comment, sign in
-
-
The transformation of pharma from an industry perceived as one putting profit before people to one with patients front and center is underway, but we still need to accelerate partnerships to reach the ultimate end goal. Download Reuters brand new white paper to learn more: https://bit.ly/3A3EHbw Hear from Boehringer Ingelheim, Novartis, Deloitte, ViiV Healthcare and more to stay ahead of the curve when it comes to patient-centric care in the months to come!
Pharma has long been guilty of putting profit before people, but that's beginning to change. While there's still a long road ahead, patient-engagement efforts are steadily improving.
1.reutersevents.com
To view or add a comment, sign in
-
Unlock six business opportunities for pharma companies investing in digital health solutions 🔓🚀. Gain insights from industry experts and explore three key enablers for successful digital health solutions, including how to build effective partnerships between pharma and digital health companies. S3 Connected Health, Roche, ViiV Healthcare #DigitalHealth #ypsomed #DigitalPartnership #SelfcareSolutions #pharma
Access the whitepaper now!
yds.ypsomed.com
To view or add a comment, sign in
-
Our latest M&A trends reveal how M&A will continue to be a critical tool to unlock value and innovation across Health, Pharma and Life Sciences. This was echoed in our latest UK #ValueCreation roundtable with Alan Milburn and senior industry dealmakers. From funding to integration, we discussed the role and importance of transactions to create sustained value. Check out our latest #PwCDeals #IndustryTrends to find out more https://pwc.to/3VM4qMG
Global M&A trends in health industries: 2024 mid-year outlook
pwc.com
To view or add a comment, sign in
-
Results from a live poll during Bain's Global Healthcare Private Equity webinar earlier today. With various headwinds resulting in softened deal volume in 2023, 2024 healthcare and life sciences M&A is shaping up to be an attractive end market for investors in verticals such as pharma services, PPM, home health, HCIT, MedTech, and biopharma.
To view or add a comment, sign in
-
-
MEDSIR leading the conversation at the Nexus Conference - 21st BioPharma Clinical Trials! During an insightful panel discussion, Rui Rui Zhang Xiang, Business Director, highlights on the evolving landscape of clinical trials across different regions. Addressing the unique challenges, she emphasized the need for innovation: "If we want to achieve different results, we must approach things differently. Today, we can’t run clinical trials the way we did in the past. We need to explore alternative approaches and adopt adaptive clinical trials to execute efficiently and optimize outcomes." Stay tuned for insights and key takeaways on #clinicaltrials ! #Biopharma #PharmaInnovation
To view or add a comment, sign in